Immunocore Holdings plc is a biotechnology business based in the US. Immunocore shares (IMCR) are listed on the NASDAQ and all prices are listed in US Dollars. Immunocore employs 291 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Immunocore
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Immunocore stock price (NASDAQ: IMCR)Use our graph to track the performance of IMCR stocks over time.
Immunocore shares at a glance
|Latest market close||$34.28|
|52-week range||$26.00 - $61.99|
|50-day moving average||$31.72|
|200-day moving average||$36.96|
|Wall St. target price||$52.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.04|
Buy Immunocore shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Immunocore stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immunocore price performance over time
|1 week (2021-09-10)||7.02%|
|1 month (2021-08-18)||14.65%|
|3 months (2021-06-18)||-16.33%|
|6 months (2021-03-19)||-21.07%|
|1 year (2020-09-15)||N/A|
|2 years (2019-09-15)||N/A|
|3 years (2018-09-15)||N/A|
|5 years (2016-09-15)||N/A|
|Revenue TTM||$28.1 million|
|Gross profit TTM||$30.1 million|
|Return on assets TTM||-27.45%|
|Return on equity TTM||-78.54%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
Shorting Immunocore shares
There are currently 167,691 Immunocore shares held short by investors – that's known as Immunocore's "short interest". This figure is 53.9% down from 363,535 last month.
There are a few different ways that this level of interest in shorting Immunocore shares can be evaluated.
Immunocore's "short interest ratio" (SIR)
Immunocore's "short interest ratio" (SIR) is the quantity of Immunocore shares currently shorted divided by the average quantity of Immunocore shares traded daily (recently around 98064.912280702). Immunocore's SIR currently stands at 1.71. In other words for every 100,000 Immunocore shares traded daily on the market, roughly 1710 shares are currently held short.
To gain some more context, you can compare Immunocore's short interest ratio against those of similar companies.
However Immunocore's short interest can also be evaluated against the total number of Immunocore shares, or, against the total number of tradable Immunocore shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunocore's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Immunocore shares in existence, roughly 0 shares are currently held short) or 0.0068% of the tradable shares (for every 100,000 tradable Immunocore shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunocore.
Find out more about how you can short Immunocore stock.
Immunocore share dividends
We're not expecting Immunocore to pay a dividend over the next 12 months.
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom. .
Stocks similar to Immunocore
Immunocore in the news
iECURE Appoints Brian Di Donato to Board of Directors
new option listings and two option delistings on September 15th
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
Frequently asked questionsWhat percentage of Immunocore is owned by insiders or institutions?
Currently 22.092% of Immunocore shares are held by insiders and 35.329% by institutions. How many people work for Immunocore?
Latest data suggests 291 work at Immunocore. When does the fiscal year end for Immunocore?
Immunocore's fiscal year ends in December. Where is Immunocore based?
Immunocore's address is: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY What is Immunocore's ISIN number?
Immunocore's international securities identification number is: US45258D1054
More guides on Finder
How to buy MiNK Therapeutics (INKT) stock when it goes public
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
How to buy Wetouch Technology (WETH) stock when it goes public
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
How to buy Life Time Group Holdings (LTH) stock when it goes public
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
How to buy Slinger Bag stock when it goes public
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
How to buy NSTS Bancorp (NSTS) stock when it goes public
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
How to buy Volcon (VLCN) stock when it goes public
Everything we know about the Volcon IPO, plus information on how to buy in.
How to buy Thomas James Homes (TJH) stock when it goes public
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
How to buy FGI Industries (FGI) stock when it goes public
Everything we know about the FGI Industries IPO, plus information on how to buy in.
How to buy Zhong Yang Financial Group (TOP) stock when it goes public
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
How to buy Exscientia Ltd (EXAI) stock when it goes public
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
Ask an Expert